65
Participants
Start Date
December 24, 2012
Primary Completion Date
July 26, 2017
Study Completion Date
July 26, 2017
Imatinib Mesylate and Nilotinib
"For patients under Imatinib Mesylate: the total length of follow up period for those patients will be for 52 weeks following IM treatment, with a follow up at weeks IM4, IM8, IM12, IM26, IM38 and IM52.~For patients requiring a salvage phase: after the switch for nilotinib, the total length of follow up period for this phase will be for 52 weeks following nilotinib treatment, with a follow up at weeks nilo4, nilo8, nilo12, nilo26, nilo38 and nilo52."
Diseases of Blood Service HURIEZ hospital CHRU de LILLE, Lille
CHU Sart Tilman, Liège
CHU d'Amiens, Amiens
CHU d'Angers, Angers
CHU Besançon, Besançon
CHU Bordeaux, Bordeaux
Hopital Morvan, Brest
CHU Clémenceau, Caen
HIA de Percy, Clamart
CHU de Clermont Ferrand, Clermont-Ferrand
CHU Grenoble, Grenoble
Centre hospitalier et régional de Lille, Lille
CHU de Lyon, Lyon
Institut Paoli Calmettes, Marseille
Hôpital Saint Eloi, Montpellier
CHU Hotel Dieu, Nantes
CHU de Nice, Nice
Hopital NECKER, Paris
Hôpital pitié Salpetrière, Paris
Centre Henri Becquerel, Rouen
CHU de STRASBOURG, Strasbourg
CHU Purpan, Toulouse
Collaborators (1)
Novartis
INDUSTRY
University Hospital, Lille
OTHER